<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2-404-09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2009
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ASPICOT 100 MG E.C. TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ACETYLSALICYLIC ACID
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Enteric-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        OTC
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        0.7
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PHARMALINE" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PHARMALINE
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 612]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrehman Algosaibi G.T.C.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            PHARMALINE
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N02BA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        B01AC06
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>This medicine contains the active substance acetylsalicylic acid. It belongs to a group of medicines called antiplatelet agents that help prevent your blood cells sticking together and forming a blood clot.</p><p>&nbsp;</p><p>This medicine is principally used to prevent blood clots forming following a heart attack or stroke or to help prevent heart attacks and strokes in patients who have previously suffered from these conditions. This medicine may have been prescribed to you if you have recently had a by-pass surgery.</p><p>&nbsp;</p><p>The tablets have been specially coated (enteric coating) to help minimize stomach upset and feeling sick (sometimes experienced as side effects of these tablets see Section 4).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Aspicot:</strong></p><p>- if you are allergic (hypersensitive) to acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs) e.g. ibuprofen, or any of the other ingredients of this medicine (listed in section 6).</p><p>An allergic reaction may be recognized as a rash, itching, swollen face or lips, shortness of breath or runny nose.</p><p>- if you are or have been suffering from a stomach ulcer, duodenal ulcer or other stomach disorders</p><p>- if you are already taking acetylsalicylic acid or any other NSAIDs</p><p>- if you have a hereditary bleeding disease where your blood does not clot properly (e.g.</p><p>haemophilia)</p><p>- if you have or have had gout</p><p>- if you are taking anti-coagulant drugs to thin your blood such as warfarin</p><p>&nbsp;</p><p><strong>Warnings and precautions:</strong></p><p>Talk to your doctor or pharmacist before taking Aspicot.</p><p>&nbsp;</p><p>Take special care with Aspicot:</p><p>- if you are starting long-term therapy following a heart attack or stroke</p><p>- if you suffer from asthma, or other allergies</p><p>- if you have problems with your kidneys or liver</p><p>&nbsp;</p><p>Please consult your doctor or pharmacist even if these statements were applicable to you at any time in the past.</p><p>&nbsp;</p><p>You should let your doctor know you are taking this medicine, particularly if you are going to have an operation, as you may need to stop taking your tablets several days before the operation.</p><p>&nbsp;</p><p><strong>Childrens and adolescents:</strong></p><p>This medicine is not intended for children under 16 years of age as there is a risk of Reye s syndrome. Reye s syndrome is a very rare disease that can be fatal.</p><p>&nbsp;</p><p><strong>Other medicines and Aspicot:</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines including medicines obtained without a prescription.</p><p>The effects of treatment may be influenced if Aspicot is taken at the same time as other medicines for:</p><p>- Thinning of the blood or prevention of clots (e.g. warfarin, heparin and phenindione)</p><p>- Organ rejection after transplantation (e.g. ciclosporin, tacrolimus)</p><p>- High blood pressure (e.g. diuretics and ACE-inhibitors)</p><p>- Pain and inflammation (e.g. anti-inflammatory medicines such as ibuprofen or steroids)</p><p>- Gout (e.g. probenecid)</p><p>- Cancer or rheumatoid arthritis (e.g. methotrexate)</p><p>- Iron salts (for treatment of iron deficiency anemia), carbonates (treatment of peptic ulcer and reflux),</p><p>alkali hydroxides (antacids)</p><p>- Phenytoin or sodium valproate (use in the treatment of epilepsy)</p><p>- Insulin and sulphonylurea hypoglycemic agents (used in the treatment of diabetes)</p><p>- Digoxin (used to treat heart problems)</p><p>- Corticosteroids</p><p>- Alcohol</p><p><strong>Pregnancy and breast-feeding:</strong></p><p><strong>&nbsp;</strong></p><p><u>Pregnancy Category C:</u></p><p>Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but the benefits from the use of the drug in pregnant women may be acceptable despite its potential risks.</p><p><u>Pregnancy Category D in third trimester:</u></p><p>&nbsp;There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but the potential benefits from the use of the drug in pregnant women may be acceptable despite its potential risks.</p><p><strong>&nbsp;</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines:</strong></p><p>This medicine has no influence on your ability to drive or use machines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>Taking this medicine:</strong></p><p>- For adults (including elderly and children over 16 years), the usual dose for the long-term management of cardiovascular disease (disease affecting the blood supply to the heart), cerebrovascular disease (disease affecting the blood supply to the brain) or following by-pass surgery is one or two tablets once daily.</p><p>- In some circumstances your doctor may advise a higher dose of up to three tablets daily.</p><p>- This medicine is intended for oral use.</p><p>- The tablets should be swallowed whole with water.</p><p>- Do not chew, crush or break the tablets.</p><p><strong>If you take more Aspicot than you should</strong></p><p>If you take more of this medicine than your doctor has prescribed go to your nearest hospital or contact your doctor immediately. Take the medicine or this leaflet with you.</p><p>Symptoms of an overdose include: vomiting, dehydration, ringing in the ear (tinnitus), vertigo, headache, nausea, dizziness, restlessness, heart failure, breathing failure, deafness, sweating, warm extremities with racing pulse, increased breathing rate and hyperventilation.</p><p>&nbsp;</p><p><strong>If you forget to take Aspicot</strong></p><p>If you forget to take a dose, take it as soon as you remember unless it is time for your next dose. In that case, just carry on with the next dose as normal. Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Stop taking this medicine and contact your doctor immediately if you experience any of the following:</p><p>- allergic reaction (hypersensitivity) which may include itching, skin rash, swelling of the hands, feet, ankles, face, lips, mouth or throat which may cause difficulties in swallowing or breathing.</p><p>- severe or persistent indigestion, nausea or fainting, stomach upset or pain, you may develop ulcers or bleeding from the stomach which can cause severe stomach pain, bloody or black tarry stools or blood vomiting.</p><p>- salt and water retention, worsening of kidney function.</p><p>- unusual or excessive bleeding.</p><p>&nbsp;</p><p>Other possible side effects:</p><p>Anemia and other blood disorders, mouth ulcers, increased tendency to infections, bruising more easily, diarrhea, blood in the urine, Stevens-Johnson syndrome (fever, rash, sore mouth and eyes, joint and muscle aches), liver problems (particularly with high doses).</p><p>&nbsp;</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- Keep this medicine out of the sight and reach of children.</p><p>- Do not use this medicine after the expiry date which is stated on the blister and the outer packaging.</p><p>The expiry date refers to the last day of that month.</p><p>- Store below 30&ordm;C. Do not refrigerate.</p><p>- Keep away from light and humidity.</p><p>- Do not use this medicine if you notice visible signs of deterioration.</p><p>- Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substance is acetylsalicylic acid.</p><p>&nbsp; Each enteric-coated tablet contains 100 mg of acetylsalicylic acid.</p><p>- The other ingredients are colloidal anhydrous silica, maize starch, microcrystalline &nbsp;cellulose, stearic acid, talc, simethicone emulsion, triethyl citrate, methacrylic acid-ethyl acrylate copolymer.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                White, round, enteric-coated tablets.
Aspicot is available in boxes containing 30 tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pharmaline, sal Lebanon</p><p>P.O. Box 90201 Jdeidet-El-Metn, Lebanon</p><p>Contact us: pharmaline@maliagroup.com</p><p>Reg. No. for Aspicot: 261088/97</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                October 2012.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي هذا الدواء على مادة حمض أسيتيل الساليسيليك الناشطة وهو ينتمي إلى مجموعة الأدوية المعروفة</p><p dir="RTL">بمضادات الصفيحات التي تساعد على منع تلاصق كريات الدم وتخثرها.</p><p dir="RTL">يسُتخدم هذا الدواء بشكل أساسي لمنع تخثر الدم إثر نوبة قلبية أو سكتة دماغية أو للمساعدة على الحماية من النوبات القلبية والسكتات الدماغية لدى المرضى الذين سبق أن عانوا من هذه المشاكل. قد يكون هذا الدواء قد ؤُصف لك إذاكنتَ قد خضعت لعملية جراحية مؤخراً.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تستخدم أق ا رص أسبيكوت:</p><p dir="RTL">- إذا كنت تعاني من الحساسية (فرط الحساسية) من حمض أسيتيل الساليسيليك أو غيره من مضادات الإلتهاب</p><p dir="RTL">اللاستيرويدية، مثل الآيبوبروفين أو أي من مكونات هذا الدواء الأخرى (المُدرجة في القسم ٦).</p><p dir="RTL">يمكن التعرف على الحساسية من خلال الطفح الجلدي، و الحكاك، تورم الوجه أو الشفتين، وضيق في التنفس أو سيلان الأنف.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-إذا كنت تعاني أو عانيت سابقاً من قرحة المعدة أو قرحة الاثني عشر أو اضط ا ربات معوية أخرى.</p><p dir="RTL">-إذا كنتَ تتناول حمض أسيتيل الساليسيليك أو أي أدوية لاستيرويدية أخرى مضادة للإلتهاب.</p><p dir="RTL">- إذا كنت تعاني من مرض نزيف و ا رثي بحيث لا يتخثر دمك بشكل سليم (مثلاً الهيموفيليا).</p><p dir="RTL">- إذا كنتَ تعاني أو عانيت سابقاً من النقرس /داء المفاصل.</p><p dir="RTL">- إذا كنتَ تتناول مضادات التخثر /موانع التجلّط لتمييع الدم مثل الوارفارين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات</strong><strong> </strong><strong>والاحتياطات</strong><strong>:</strong></p><p dir="RTL">عليك استشارة طبيبك المعالج أو الصيدلي قبل استخدام أسبيكوت.</p><p dir="RTL">خاصة:</p><p dir="RTL">- إذا كنت تبدأ بعلاج طويل الأمد بعد تعرضك لذبحة قلبية أو سكتة دماغية.</p><p dir="RTL">- إذا كنت تعاني من الربو أو أنواع أخرى من الحساسية.</p><p dir="RTL">- إذا كنت تعاني من مشاكل في الكلى أو الكبد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الرجاء مراجعة الطبيب المعالج أو الصيدلي حتىّ وإن كانت الحالات السابقة تنطبق عليك في أي مرحلة سابقة من حياتك.</p><p dir="RTL">عليك إعلام طبيبك بأنك تتناول هذا الدواء لا سيما إذا كنتَ سوف تخضع لعملية إذ قد تحتاج إلى التوقف عن تناول الأقراص قبل أيام عديدة من العملية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأولاد</strong><strong> </strong><strong>والمراهقون</strong></p><p dir="RTL">لا يوصف هذا الدواء للأولاد ما دون ال ۱٦ سنة بسبب خطر إصابتهم بمتلازمة ا ري وهي داء نادر جداً قد يكون مميتاً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أدوية</strong><strong> </strong><strong>أخرى</strong><strong> </strong><strong>وأقراص</strong><strong> </strong><strong>أسبيكوت</strong><strong>:</strong></p><p dir="RTL">ينبغي على المريض إطلاع الطبيب أو الصيدلي على أي أدوية أخرى يتناولها أو تناولها في الفترة الأخيرة أو قد يتناولها بما فيها الأدوية التي حصل عليها بدون وصفة طبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يتأثر مفعول العلاج إذا تم تناول أسبيكوت بالتزامن مع أدوية أخرى لـ:</p><p dir="RTL">- تمييع الدم أو منع تخثره (مثلا الوارفارين، الهيبارين والفينينديون)</p><p dir="RTL">- رفض الجسم للعضو الجديد بعد عملية زرع أعضاء (مثلا السيكلوسبورين، التاكروليموس)</p><p dir="RTL">- ارتفاع ضغط الدم (مثلا مدرات البول ومثبطات إيس)</p><p dir="RTL">- الألم والالتهاب( مثلا الأدوية المضادة للإلتهاب مثل الآيبوبروفين والستيروييدات)</p><p dir="RTL">- النقرس/داء المفاصل (مثلا البروبينيسيد)</p><p dir="RTL">- السرطان أو داء المفاصل الروماتويدي (مثلا الميتوتريكسات)</p><p dir="RTL">- أملاح الحديد (لمعاجة أنيميا نقص الحديد)، الكربونات (لمعالجة القرحة الهضمية والجزْر)، هيدروكسيدات الفلزات (مضادات الحموضة)</p><p dir="RTL">- الفينيتوين وفالبروات الصوديوم (المستعملة لمعالجة داء الصرع)</p><p dir="RTL">- الأنسولين وعامل سولفونيلوريا سكّر الدم (المستعملة لمعالجة مرضى السكري)</p><p dir="RTL">- الديجوكسين (المستخدم لمعالجة مشاكل القلب)</p><p dir="RTL">- الكورتيكوستيرويدات</p><p dir="RTL">- الكحول</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل</strong><strong> </strong><strong>والرضاعة</strong><strong>:</strong></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>فئة </u><u>: C</u></p><p dir="RTL">&nbsp;&nbsp;<em>U</em></p><p dir="RTL">أظهرت نتائج الدراسات التي أجريت على أجنة الحيوانات اّثارا جانبية و لم توجد دراسات سريريه محكمة و كافية وكانت منافع استخدام الدواء على المرأة الحامل مقبولة إلى حد ما على الرغم من الخطورة المحتملة على الجنين</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>فئة </u><u>: D</u></p><p dir="RTL">هناك دليل إيجابي على وجود خطر على الجنين إعتمادا على بيانات الآثار الجانبية من الدراسات أو الخبرات التسويقية أو البحثية.</p><p dir="RTL">على البشر، و لكن الفوائد المحتملة من إستخدام هذا الدواء للنساء الحوامل يكون مقبولا على الرغم من المخاطر المحتملة.</p><p dir="RTL">&nbsp;إذا كنتِ حاملاً، تقومين بالإرضاع، تعتقدين أنك حامل، أو تخططين لإنجاب طفل، عليكِ استشارة طبيبك أو الصيدلي قبل البدء بتناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة</strong><strong> </strong><strong>واستخدام</strong><strong> </strong><strong>المكنات</strong></p><p dir="RTL">لا يؤثر هذا الدواء على قدرة المريض على القيادة واستخدام المكنات.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتعين على المريض تناول كبسولات أسبيكوت تماماً حسب وصفة الطبيب وعليه استشارته أو استشارة الصيدلي إذا لم يكن أكيد اً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناوُل</strong><strong> </strong><strong>هذا</strong><strong> </strong><strong>الدواء</strong></p><p dir="RTL">- بالنسبة إلى ال ا رشدين (بمن فيهم الشيوخ والأولاد ما فوق ال ۱٦ عاماً)، الجرعة الاعتيادية للمعالجة الطويلة الأمد لأمراض القلب الوعائية (مرض يؤثر على دفق الدم إلى القلب)، ومرض الأوعية الدماغية (مرض يؤثر على دفق الدم إلى الدماغ) أو بعد الخضوع لعملية ج ا رحية هي قرص واحد أو قرصان يومياً.</p><p dir="RTL">- في بعض الحالات، يمكن أن يصف الطبيب جرعة أكبر قد تصل إلى ۳ قراص يومياً.</p><p dir="RTL">- يتم تناول هذا الدواء عبر الفم.</p><p dir="RTL">- يتم ابتلاع حبة الدواء كاملة مع المياه.</p><p dir="RTL">- لا يُمضغ هذا الدواء ولا يُطحن ولا يُكسر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في</strong><strong> </strong><strong>حال</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>المريض</strong><strong> </strong><strong>جرعة</strong><strong> </strong><strong>من</strong><strong> </strong><strong>قراص</strong><strong> </strong><strong>أسبيكوت</strong><strong> </strong><strong>أكثر</strong><strong> </strong><strong>مما</strong><strong> </strong><strong>يجب</strong></p><p dir="RTL">في حال تناول المريض جرعات من هذا الدواء أكثر مما وصفه الطبيب عليه الإتصال بطبيبه مباشرة أو التوجه إلى أقرب مستشفى آخذاً الدواء أو هذا الدليل معه.</p><p dir="RTL">تشمل أ عراض الجرعة الزائدة: تقيؤ، نقص الماء في الجسم، رنين في الأ ذن (طنين)، دُوار، ألم في الرأس، غثيان، دوخة، أرق، نوبة قلبية، ضيق تنفس، صمم/طرش، تعرّق، أط ا رف دافئة مع تسارع في النبض، تزايد وتيرة التنفس، وفرط التنفس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في</strong><strong> </strong><strong>حال</strong><strong> </strong><strong>نسي</strong><strong> </strong><strong>المريض</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>قراص</strong><strong> </strong><strong>أسبيكوت</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">في حال نسي المريض تناول إحدى الجرعات، عليه تناولها حالما يتذكّر إلا إذا اقترب موعد الجرعة التالية. ففي هذه الحالة، عليه أن ينسى أمر الجرعة التي لم يتناولها ويتابع جدول الجرعات المعتادة. لا يجب تناول جرعة مضاعفة للتعويض عن الجرعة التي لم يتم تناولها.</p><p dir="RTL">إذا كانت لدى المريض أي أسئلة إضافية حول استخدام هذا الدواء، عليه مراجعة الطبيب أو الصيدلي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شأن أسبيكوت شأن كافة الأدوية فقد يتسبّب بآثار جانبية على الرغم من أنها لا تصيب الجميع.</p><p dir="RTL">إذا واجه المريض أياً مما يلي، عليه التوقف عن تناول هذا الدواء وٕاطلاع طبيبه مباشرة:</p><p dir="RTL">- حساسية (حساسية مفرطة) قد تشمل الحكاك، الطفح الجلدي، انتفاخ اليدين، القدمي ن، الكاحلين، الوجه، الشفتين، الفم أو الحلق مما قد يسبب صعوبة في الإبتلاع أو التنفس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">- عسر هضم شديد أو مستمر، غثيان أو إغماء، اضط ا ربات أو ألم في المعدة، كما قد يتعرض المريض إلى حصول قرحة أو نزيف من المعدة يمكن أن يسبب ألماً حاداً في المعدة، خروج براز أسود اللون أو فيه دم أو إلى تقيؤ دم.</p><p dir="RTL">- احتفاظ الجسم بالأملاح أو المياه، وتدهور وظيفة الكلى.</p><p dir="RTL">- نزيف غير اعتيادي أو مفرط.</p><p dir="RTL">&nbsp;</p><p dir="RTL">آثار جانبية محتملة أخرى<strong>:</strong></p><p dir="RTL">فقر دم واضط ا ربات أخرى في الدم، تقرحات في الفم، ميل أكبر للإصابة بالعدوى، ظهور كدمات بسرعة أكبر، إسهال، دم في البول، متلازمة ستيفنس جونسون (حمّى، طفح جلدي، التهاب في الفم والعينين، آلام في المفاصل والعضلات ،مشاكل في الكبد (لا سيما لدى تناول الجرعات الكبيرة).</p><p dir="RTL">إذا تعرضت لأي من الآثار الجانبية هذه، عليك استشارة طبيبك أو الصيدلي. يشمل هذا أي آثار جانبية محتملة غير مدرجة في هذا الدليل.</p><p dir="RTL">للإبلاغ عن أي آثار جانبية:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المملكة</strong><strong> </strong><strong>العربية</strong><strong> </strong><strong>السعودية</strong><strong>:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">معلومات الاتصال بالمركز الوطني للتيقظ و السلامة الدوائية حسب ما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرقم المجاني: 8002490000</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: <em>U</em>www.sfda.gov.sa/npc<em>U</em></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب إبقاء هذا الدواء بعيداً عن متناول الأطفال وعن مرآهم.</p><p dir="RTL">-يجب ألا يُستخدم هذا الدواء بعد انتهاء تاريخ صلاحيته المذكور على النفطة وعلى العلبة من الخارج والذي يُشير إلى اليوم الأخير من الشهر المذكور.</p><p dir="RTL">-يجب أن تُحفظ أقراص أسبيكوت في درجة حرارة دون ۳٠ &deg; مئوية. لا يُبرّد.</p><p dir="RTL">-يجب أن تبقى بعيدةً عن الضوء والرطوبة.</p><p dir="RTL">-لا تستخدم هذا الدواء في حال لاحظت إشارات واضحة للتلف.</p><p dir="RTL">-لا تتخلص من أي أدوية عبر رميها في المجاري. اسأل الصيدلي عن طريقة التخلّص من الأدوية التي لم تعد تستخدمها، لأنّ هذه الإج ا رءات سوف تساعد في حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>- </strong>مادة حمض أسيتيل الساليسيليك الناشطة.</p><p dir="RTL">كل كبسولة مغلفة تحتوي على ۱۰۰ مغ من حمض أسيتيل الساليسيليك</p><p dir="RTL">- المكونات الأخرى هي: السيليكا الغروية اللامائية، نشاء الذرة، ميكروكريستالين سيلولوز ، الحامض الدهني،</p><p dir="RTL">الطلق، مستحلب سيميثيكون، ثلاثي إيثيل السيترات ، حمض ميثاكريليك - كوبوليمر إيثيل أكريلات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">هي أ قراص مستديرة بيضاء مغلفة بغشاء.</p><p dir="RTL">أسبيكوت متوفر في علب تحوي ۳۰ قرص.</p><p dir="RTL">أسبيكوت متوفر في علب تحوي ۱۰۰ قرص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">فارمالاين ش.م.ل. - لبنان</p><p dir="RTL">صندوق البريد: ٩۰۲۰۱ جديدة المتن، لبنان</p><p>pharmaline@maliagroup.com :بنا إتصلو</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            في شهر كانون الأول من العام ۲۰۱۲
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aspicot100 mg, enteric-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains: 100 mg of acetylsalicylic acid For the full list of excipients, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                White, round, enteric-coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>- Secondary prevention of myocardial infarction.</p><p>&nbsp;- Prevention of cardiovascular morbidity in patients suffering from stable angina pectoris.</p><p>&nbsp;- History of unstable angina pectoris, except during the acute phase.</p><p>&nbsp;- Prevention of graft occlusion after Coronary Artery Bypass Grafting (CABG).</p><p>- Coronary angioplasty, except during the acute phase.</p><p>- Secondary prevention of transient ischemic attacks (TIA) and ischemic cerebrovascular accidents (CVA), provided intracerebralhemorrhages have been ruled out.</p><p>Aspicot is not recommended in emergency situations. It is restricted to secondary prevention with chronic treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Adults</u></p><p>For the management of cardiovascular or cerebrovascular disease:</p><p>The advice of a doctor should be sought before commencing therapy for the first time. The usual dosage, for long term use, is 100-200 mg once daily. In some circumstances a higher dose may be appropriate, especially in the short term, and up to 300 mg a day may be used on the advice of a doctor.</p><p><u>Elderly </u></p><p>In general, acetylsalicylic acid should be used with caution in elderly patients who are more prone to adverse events. The usual adult dose is recommended in the absence of severe renal or hepatic insufficiency. Treatment should be reviewed at regular intervals.</p><p><u>Pediatric population </u></p><p>Acetylsalicylic acid should not be administered to children and adolescents younger than 16 years, except on medical advice where the benefit outweighs the risk (see section 4.4).</p><p><u>Method of administration </u></p><p>For oral use.</p><p>The tablets should be swallowed whole with sufficient fluid (1/2 glass of water). Due to the gastro resistant coating the tablets should not be crushed, broken or chewed because coating prevents irritant effects on the gut.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
- Known intolerance to acetylsalicylic acidor other non-steroidal anti-inflammatory drugs (NSAIDs) orany of the other ingredients of this medicine (listed in section 6.1).
 - Acetylsalicylic acid is contraindicated in patients with active peptic ulceration or a history of peptic ulceration and those with hemophilia or other clotting disorders or gout. 
- Known hypersensitivity reactions (e.g. bronchospasm, rhinitis, urticaria) in response to acetylsalicylic acid or non-steroidal anti-inflammatory drugs. 
- Acetylsalicylic acid should not be taken concurrently with anti-coagulants.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before commencing long term acetylsalicylic acid therapy for the management of cardiovascular or cerebrovascular disease patients should consult their doctor who can advise on the relative benefits versus the risks for the individual patient.</p><p>Acetylsalicylic acid may promote bronchospasm and asthma attacks or other hypersensitivity reactions. Risk factors are existing asthma, hay fever, nasal polyps or chronic respiratory diseases. The same applies for patients who also show allergic reaction to other substances (e.g. with skin reactions, itching or urticaria).</p><p>Use with caution in cases of impaired renal or hepatic function. There is an increased risk of hemorrhage particularly during or after operative procedures (even in cases of minor procedures, e.g. tooth extraction). Use with caution before surgery, including tooth extraction. Temporary discontinuation of treatment may be necessary. Do not exceed the stated dose.</p><p>Aspicot is not indicated in children and young people less than 16 years of age. There is a risk of Reye&#39;s syndrome when children take acetylsalicylic acid.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Contraindicated combinations</u></p><p><em>Methotrexate (used at doses &gt;15 mg/week): </em></p><p>The combined drugs, methotrexate and acetylsalicylic acid, enhance hematological toxicity of methotrexate due to the decreased renal clearance of methotrexate by acetylsalicylic acid. Therefore, the concomitant use of methotrexate (at doses &gt;15 mg/week) with acetylsalicylic acidis contraindicated.</p><p><u>Not recommended combinations </u></p><p><em>Uricosuric agents, e.g. probenecid </em>Salicylates reverse the effect of probenecid. The combination should be avoided.</p><p><u>Combinations requiring precautions for use or to be taken into account</u></p><p><em>Anticoagulants e.g. coumarin, heparin, warfarin</em></p><p>Increased risk of bleeding due to inhibited thrombocyte function, injury of the duodenal mucosa and displacement of oral anticoagulants from their plasma protein binding sites. The bleeding time should be monitored.</p><p><em>Anti-platelet agents (e.gclopidogrel and dipyridamole) and selective serotonin reuptake inhibitors (SSRIs; such as sertraline or paroxetine)</em></p><p>Increased risk of gastrointestinal bleeding.</p><p><em>Antidiabetics, e.g. sulphonylureas</em></p><p><em>&nbsp;</em>Salicylates may increase the hypoglycemic effect of sulphonylureas.</p><p><em>Digoxin and lithium </em></p><p>Acetylsalicylic acid impairs the renal excretion of digoxin and lithium, resulting in increased plasma concentrations. Monitoring of plasma concentrations of digoxin and lithium is recommended when initiating and terminating treatment with acetylsalicylic acid. Dose adjustment may be necessary.</p><p><em>Diuretics and antihypertensives </em></p><p>NSAIDs may decrease the antihypertensive effects of diuretics and other antihypertensive agents. As for other NSAIDs concomitant administration with ACE-inhibitors increases the risk of acute renal insufficiency.</p><p>Diuretics: Risk of acute renal failure due to the decreased glomerual filtration via decreased renal prostaglandin synthesis. Hydrating the patient and monitoring renal function at the start of the treatment is recommended.</p><p><em>Carbonic anhydrase inhibitors (acetazolamide)</em></p><p>May result in severe acidosis and increased central nervous system toxicity.</p><p><em>Systemic corticosteroids </em></p><p>The risk of gastrointestinal ulceration and bleeding may be increased when acetylsalicylic acid and corticosteroids are co-administered.</p><p><em>Methotrexate (used at doses &lt;15 mg/week):</em></p><p><em>&nbsp;</em>The combined drugs, methotrexate and acetylsalicylic acid, may increase hematological toxicity of methotrexate due to decreased renal clearance of methotrexate by acetylsalicylic acid. Weekly blood count checks should be done during the first weeks of the combination. Enhanced monitoring should take place in the presence of even mildly impaired renal function, as well, as in elderly.</p><p><em>Other NSAIDs</em></p><p><em>&nbsp;</em>Increased risk of ulcerations and gastrointestinal bleeding due to synergistic effects.</p><p><em>Ibuprofen</em></p><p>Experimental data suggest that ibuprofen may inhibit the effect of low dose acetylsalicylic acid on platelet aggregation when they are dosed concomitantly. However, the limitations of these data and the uncertainties regarding extrapolation of ex vivo data to the clinical situation imply that no firm conclusions can be made for regular ibuprofen use, and no clinically relevant effect is considered to be likely for occasional ibuprofen use (see section 5.1).</p><p><em>Ciclosporin, tacrolimus </em></p><p>Concomitant use of NSAIDs and ciclosporin or tacrolimus may increase the nephrotoxic effect of ciclosporin and tacrolimus. The renal function should be monitored in case of concomitant use of these agents and acetylsalicylic acid.</p><p><em>Valproate</em></p><p><em>&nbsp;</em>Acetylsalicylic acid has been reported to decrease the binding of valproate to serum albumin, thereby increasing its free plasma concentrations at steady state.</p><p><em>Phenytoin</em></p><p><em>&nbsp;</em>Salicylate diminishes the binding of phenytoin to plasma albumin. This may lead to decreased total phenytoin levels in plasma, but increased free phenytoin fraction. The unbound concentration, and thereby the therapeutic effect, does not appear to be significantly altered.</p><p><em>Iron salts, alkalis and antacids:</em></p><p><em>&nbsp;</em>Acetylsalicylic acid is pharmaceutically incompatible with iron salts and alkalis. Antacids will reduce the effect of acetylsalicylic acid.</p><p><em>Alcohol </em></p><p>Concomitant administration of alcohol and acetylsalicylic acid increases the risk of gastrointestinal bleeding.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p><u>Pregnancy Category C:</u></p><p>Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but the benefits from the use of the drug in pregnant women may be acceptable despite its potential risks.</p><p><u>Pregnancy Category D in third trimester:</u></p><p>&nbsp;There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but the potential benefits from the use of the drug in pregnant women may be acceptable despite its potential risks.</p><p>Acetylsalicylic acid is best avoided in late pregnancy and during breast-feeding as it may prolong labour and cause bleeding in the neonate.</p><p>High doses of acetylsalicylic acid may result in closure of fetal ductusarteriosus<em>in utero </em>and possibly persistent pulmonary hypertension in the new born.</p><p>&nbsp;Kernicterus may be a consequence of jaundice in neonates.</p><p>Acetylsalicylic acid should be avoided during lactation, as there is a risk of Reye&#39;s syndrome.</p><p>Regular use of high doses could impair platelet function and produce hypothrombinemia in the infant if neonatal vitamin K stores are low.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed with acetylsalicylic acid.</p><p>Based on the pharmacodynamic properties and the side effects of acetylsalicylic acid, no influence on the reactivity and the ability to drive or use machines is expected.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Side effects are grouped on the basis of System Organ Class. Within each system organ class the frequencies are defined as: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000) and not known (cannot be estimated from the available data)</p><p><img alt="" width="682" height="643" src="data:image/png;base64,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" /></p><p><img alt="" width="644" height="550" src="data:image/png;base64,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" /></p><p><strong>To report any side effect(s): </strong></p><p>&nbsp;</p><p>&bull; <strong><em>Saudi Arabia:</em></strong></p><p>- The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>&nbsp;o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Although considerable inter-individual variations are involved, it can be considered that the toxic dose is about 200 mg/kg in adults and 100 mg/kg in children. The lethal dose of acetylsalicylic acid is 25-30 grams. Plasma salicylate concentrations above 300 mg/l indicate intoxication. Plasma concentrations above 500 mg/l in adults and 300 mg/l in children generally cause severe toxicity.</p><p>Overdose may be harmful for elderly patients and particularly for small children (therapeutic overdose or frequent accidental intoxications may be fatal).</p><p><u>Symptoms of moderate intoxications </u></p><p>Tinnitus, hearing disorders, headache, vertigo, confusion and gastrointestinal symptoms (nausea, vomiting and abdominal pain).</p><p><u>Symptoms of severe intoxications </u></p><p>Symptoms are related to severe disruption of the acid-base balance. In the first instance hyperventilation occurs, which results in respiratory alkalosis. Respiratory acidosis ensues due to suppression of the respiratory centre. In addition, metabolic acidosis occurs as a result of the presence of salicylate. Since younger children are often not seen until they have reached a late stage of intoxication, they are usually in the stage of acidosis.</p><p>Furthermore, the following symptoms may occur: hyperthermia and perspiration, resulting in dehydration: feelings of restlessness, convulsions, hallucinations and hypoglycemia. Depression of the nervous system may lead to coma, cardiovascular collapse or respiratory arrest.</p><p><u>Treatment of overdose </u></p><p>If a toxic dose has been ingested, hospital admission is required. In the event of moderate intoxication, inducing the patient to vomit should be attempted.</p><p>If this fails, gastric lavage may be attempted during the first hour after ingestion of a substantial amount of the medicine. Afterwards, administer activated carbon (adsorbent) and sodium sulphate (laxative).</p><p>Activated charcoal may be given as a single dose (50 g for an adult, 1 g/kg body weight for a child up to 12 years).</p><p>&nbsp;Alkalization of the urine (250 mmol NaHCO3, for three hours) whilst checking urine pH levels may be considered.</p><p>In the event of severe intoxication, hemodialysis is to be preferred.</p><p>Other symptoms are to be treated symptomatically.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antithrombotic agents: platelet aggregation inhibitors excl. heparin, ATC code: B01AC06.</p><p>Acetylsalicylic acid inhibits the platelet activation: blocking the platelet cyclooxygenase by acetylation, it inhibits thromboxane A2 synthesis, a physiological activating substance released by the platelets and which plays a role in the complications of the atheromatosic lesions.</p><p>Inhibition of TXA2-synthesis is irreversible, because thrombocytes, which have no nucleus, are not capable (due to lack of protein synthesis capability) to synthesize new cyclooxygenase, which had been acetylated by acetylsalicylic acid.</p><p>The repeated doses from 20 to 325 mg involve an inhibition of the enzymatic activity from 30 to 95%.</p><p>Due to the irreversible nature of the binding, the effect persists for the lifespan of a thrombocyte (7-10 days). The inhibiting effect does not exhaust during prolonged treatments and the enzymatic activity gradually begins again upon renewal of the platelets 24 to 48 hours after treatment interruption.</p><p>Acetylsalicylic acid extends bleeding time on average by approximately 50 to 100%, but individual variations can be observed.</p><p>Experimental data suggest that ibuprofen may inhibit the effect of low dose acetylsalicylic acid on platelet aggregation when they are dosed concomitantly.</p><p>In one study, when a single dose of ibuprofen 400 mg was taken within 8 h before or within 30 min after immediate release acetylsalicylic acid dosing (81 mg), a decreased effect of acetylsalicylic acid on the formation of thromboxane or platelet aggregation occurred. However, the limitations of these data and the uncertainties regarding extrapolation of ex vivo data to the clinical situation imply that no firm conclusions can be made for regular ibuprofen use, and no clinically relevant effect is considered to be likely for occasional ibuprofen use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption </u></p><p>After oral administration, acetylsalicylic acid is rapidly and completely absorbed from the gastrointestinal tract. The principal site of absorption is the proximal small intestine. However, a significant portion of the dosage is already hydrolyzed to salicylic acid in the intestinal wall during the absorption process. The degree of hydrolysis is dependent on the rate of absorption.</p><p>After intake of acetylsalicylic acid the maximum plasma levels of acetylsalicylic acid and salicylic acid are reached after about 5 hours and 6 hours, respectively, following administration in the fasted state. If the tablets are taken with food, maximum plasma levels are reached approximately 3 hours later than in the fasted state.</p><p><u>Distribution </u></p><p>Acetylsalicylic acid as well as the main metabolite salicylic acid, are extensively bound to plasma proteins, primarily albumin, and distributed rapidly into all parts of the body. The degree of protein binding of salicylic acid is strongly dependant of both the salicylic acid and albumin concentration. The volume of distribution of acetylsalicylic acid is ca. 0.16 l/kg of body weight. Salicylic acid slowly diffuses into the synovial fluid, crosses the placental barrier and passes into breast milk.</p><p><u>Biotransformation </u></p><p><u>&nbsp;</u></p><p>Acetylsalicylic acid is rapidly metabolized to salicylic acid, with a half-life of 15-30 minutes. Salicylic acid is subsequently predominantly converted into glycine and glucuronic acid conjugates, and traces of gentisic acid.</p><p>Elimination kinetics of salicylic acid is dose-dependent, because the metabolism is limited by liver enzyme capacity. Thus, elimination half-time varies and is 2-3 hours after low doses, 12 hours after usual analgetic doses and 15-30 hours after high therapeutic doses or intoxication.</p><p>&nbsp;</p><p><u>Excretion </u></p><p>Salicylic acid and its metabolites are predominantly excreted via the kidneys.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The preclinical safety profile of acetylsalicylic acid is well documented.</p><p>&nbsp;In experimental animal studies, salicylates have shown no other organ injury than renal damage. In rat studies, fetotoxicity and teratogenic effects were observed with acetylsalicylic acid at maternotoxic doses. Clinical relevance is unknown as the doses used in non-clinical studies are much higher (7 times at least) than the maximal recommended doses in targeted cardiovascular indications.</p><p>Acetylsalicylic acid was extensively investigated with regard to mutagenic and carcinogenic effects. The results as a whole show no relevant signs for any mutagenic or carcinogenic effects in mice and rat studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core:</u></p><p>Colloidal anhydrous silica</p><p>Maize starch</p><p>Microcrystalline cellulose</p><p>Stearic acid</p><p>&nbsp;</p><p><u>Film-coating: </u></p><p>Methacrylic acid-ethyl acrylate copolymer</p><p>Triethyl citrate</p><p>Simethicone emulsion</p><p>Talc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C.</p><p>Do not refrigerate. Keep away from light and humidity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>30 enteric coated tablets filled in 3 Aluminum lid stock &amp; opaque PVC/PE/PVdCblisters and packed in carton box with leaflet inside.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pharmaline, sal – Lebanon P.O. Box 90201 Jdeidet-El-Metn, Lebanon Contact us: pharmaline@maliagroup.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                18/11/1998
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>